Company Overview and News

 
Thirumalai Chemicals: Exposure to varied markets, capacity expansion diversification key triggers

2017-12-28 moneycontrol
Thirumalai Chemicals (Market cap: Rs 2226 cr) is the second‐largest manufacturer in the domestic phthalic anhydride (PAN) market after IG Petrochemicals. Phthalic anhydride is an ingredient for PVC (Poly Vinyl Chloride) and is also used in construction and electrical insulations. Further, Thirumalai’s value‐added product portfolio such as maleic anhydride (MAN), diethyl phthalate (DEP), and food acids has steady  demand from the food and beverage, cosmetics, animal feed industries.

 
Board of I G Petrochemicals approves expansion of Phthalic Anhydride plant

2017-09-22 indiainfoline
By clicking on submit button, you authorize IIFL & its representatives & agents to provide information about various products, offers and services provided by IIFL through any mode including telephone calls, SMS, letters etc. . you confirm that laws in relation to unsolicited communication referred in “National Do Not Call Registry” as laid down by “Telecom Regulatory Authority of India” will not be applicable for such information/ communication.

 
IG Petrochemical – in the right business at the right price?

2017-05-08 moneycontrol
In an otherwise overheated market, it is difficult to find a company that is in the right business at the right price – I G Petrochemicals happens to be one such interesting name. The company caters to the high growing segment of plastics. While the stock had a stellar run, the valuation still looks reasonable. Finally, the company has invested in improving growth and margin that stand to support earnings.

 
I G Petrochemicals spurts after stellar Q4 report card

2017-05-04 indiainfoline
I G Petrochemicals advanced 4.84% to Rs 423.80 at 09:35 IST on BSE after net profit jumped 134.31% to Rs 28.07 crore on 34.19% rise in total income to Rs 289.90 crore in Q4 March 2017 over Q4 March 2016.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...